EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 73 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer January 6, 2021 Cliff Collapse Kills Woman Celebrating Breast Cancer Victory and 2 of... August 5, 2019 ¿Los sobrevivientes del cáncer necesitan ser positivos todo el tiempo? Permitirse... October 12, 2022 Dog Showers His Mom with Snuggles and Makes Her Laugh During... December 6, 2021 Load more HOT NEWS FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC Having a Heart Attack May Make Breast Cancer Grow Faster EMA Recommends Granting a Marketing Authorisation for Asciminib EMA Recommends Extension of Indications for Atezolizumab
